These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36636885)

  • 1. Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis.
    Kang SH; Yoon EL
    Gut Liver; 2023 Jan; 17(1):8-9. PubMed ID: 36636885
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis.
    Song W; Yoo SH; Jang J; Baik SJ; Lee BK; Lee HW; Park JS
    Gut Liver; 2023 Jan; 17(1):130-138. PubMed ID: 36472070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis.
    Yu R; Shi Q; Liu L; Chen L
    BMC Gastroenterol; 2018 Apr; 18(1):51. PubMed ID: 29673321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation.
    Carias S; Castellanos AL; Vilchez V; Nair R; Dela Cruz AC; Watkins J; Barrett T; Trushar P; Esser K; Gedaly R
    J Gastroenterol Hepatol; 2016 Mar; 31(3):628-33. PubMed ID: 26399838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).
    Lee YH; Kim SU; Song K; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH
    Hepatology; 2016 Mar; 63(3):776-86. PubMed ID: 26638128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B.
    Han E; Lee YH; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH; Kim SU
    Aliment Pharmacol Ther; 2018 Aug; 48(3):300-312. PubMed ID: 29920701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
    Feng Y; Peng B; Li Y; Sun L; Sun Y
    Hepatology; 2023 May; 77(5):E103-E104. PubMed ID: 36645222
    [No Abstract]   [Full Text] [Related]  

  • 8. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease.
    Gan D; Wang L; Jia M; Ru Y; Ma Y; Zheng W; Zhao X; Yang F; Wang T; Mu Y; Zhu S
    Clin Nutr; 2020 Apr; 39(4):1124-1130. PubMed ID: 31053512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications.
    Angulo P; Machado MV; Diehl AM
    Semin Liver Dis; 2015 May; 35(2):132-45. PubMed ID: 25974899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis.
    Pan X; Han Y; Zou T; Zhu G; Xu K; Zheng J; Zheng M; Cheng X
    Dig Dis; 2018; 36(6):427-436. PubMed ID: 30048963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study.
    Petta S; Eslam M; Valenti L; Bugianesi E; Barbara M; Cammà C; Porzio M; Rosso C; Fargion S; George J; Craxì A
    Liver Int; 2017 Sep; 37(9):1389-1396. PubMed ID: 28235154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage.
    Lombardi R; Petta S; Pisano G; Dongiovanni P; Rinaldi L; Adinolfi LE; Acierno C; Valenti L; Boemi R; Spatola F; Craxì A; Fargion S; Fracanzani AL
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):517-519. PubMed ID: 30528844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
    Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes Liver Fibrosis Score to Detect Advanced Fibrosis in Diabetics with Nonalcoholic Fatty Liver Disease.
    Singh A; Garg R; Lopez R; Alkhouri N
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e624-e626. PubMed ID: 33434655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the editor: Liver outcomes after bariatric surgery in patients with NASH and advanced fibrosis.
    Jindal A
    Hepatology; 2022 Aug; 76(2):E42. PubMed ID: 35306689
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease.
    Chun HS; Kim MN; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
    J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1168-1178. PubMed ID: 34337887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.
    Li W
    J Hepatol; 2020 Aug; 73(2):465-466. PubMed ID: 32416974
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter regarding "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways".
    Liu Y; Chen M
    Clin Mol Hepatol; 2023 Jan; 29(1):163-164. PubMed ID: 36300328
    [No Abstract]   [Full Text] [Related]  

  • 19. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years.
    Kawanaka M; Nishino K; Morimoto Y; Ishii K; Tanikawa T; Urata N; Suehiro M; Sasai T; Haruma K; Kawamoto H
    Intern Med; 2021 May; 60(9):1397-1401. PubMed ID: 33281161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.